Article
Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study).
Antiviral therapy - 1 Jan 2008
Pellegrin Isabelle, Wittkop Linda, Joubert Laurence Morand, Neau Didier, Bollens Diane, Bonarek Mojgan, Girard Pierre-Marie, Fleury Hervé, Winters Bart, Saux Marie-Claude, Pellegrin Jean-Luc, Thiébaut Rodolphe, Breilh Dominique
Abstract excerpt
BACKGROUND: We assessed the association of baseline HIV-1 mutations, phenotypic sensitivity and pharmacokinetics with virological failure (VF) at week 12 (W12) after onset of a darunavir/ritonavir (DRV/r)-based regimen in a cohort of 67 antiretroviral-experienced HIV-patients failing on highly active antiretroviral therapy (HAART). METHODS: VF was defined as HIV RNA >2.3 log10copies/ml at W12. HIV reverse...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.